Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis
Top Cited Papers
- 10 January 2016
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2), 123-129
- https://doi.org/10.1200/jco.2015.62.0138
Abstract
PurposeWe performed a multi-institutional study to identify prognostic factors and determine outcomes for patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and brain metastasis.Patien...This publication has 30 references indexed in Scilit:
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 studyThe Lancet Oncology, 2014
- Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving CrizotinibInternational Journal of Radiation Oncology*Biology*Physics, 2014
- Clinical and economic outcomes of patients with brain metastases based on symptoms: An argument for routine brain screening of those treated with upfront radiosurgeryCancer, 2013
- A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung CancerClinical Cancer Research, 2013
- Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2012
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyThe Lancet Oncology, 2012
- Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialThe Lancet Oncology, 2009
- A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG DatabaseInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain MetastasesJama-Journal Of The American Medical Association, 2006
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004